Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ELLIPTA, DISKUS · 1 trial · 1 indication
The number of participants who expressed the indicated device preference (i.e., preference for ELLIPTA inhaler, preference for DISKUS inhaler, and no preference) based on the size of the numbers on the dose counter was summarized by study inhaler use sequence.
| Arm | Type | Description |
|---|---|---|
| ELLIPTA Period 1 and DISKUS Period 2 Arm | EXPERIMENTAL | Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period. |
| DISKUS Period 1 and ELLIPTA Period 2 Arm | EXPERIMENTAL | Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period. |
| Name | Type | Description |
|---|---|---|
| ELLIPTA | DEVICE | Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip) |
| DISKUS | DEVICE | Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip) |
Inclusion Criteria: * 1\. Informed consent * Subject must give their signed and dated written informed consent to participate. * Subject understands and is willing, able, and likely to comply with study procedures and restrictions. * Subject must be able to read, comprehend, and record information ...
ELLIPTA DISKUS is an investigational inhaler device combination studied for use in chronic obstructive pulmonary disease (COPD). It was evaluated in a Phase 3 clinical trial to assess patient preference between the DISKUS and ELLIPTA devices. The study enrolled 287 participants aged 40 years and older in the United States.
ELLIPTA DISKUS is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK conducted a Phase 3 clinical trial to evaluate the device preference between DISKUS and ELLIPTA in patients with chronic obstructive pulmonary disease.
ELLIPTA DISKUS is in Phase 3 clinical development. It has completed one Phase 3 trial, NCT01868009, which was a controlled, randomized study in chronic obstructive pulmonary disease. The trial is completed, and the drug remains investigational, not yet approved by regulatory authorities.
ELLIPTA DISKUS has one completed Phase 3 clinical trial, NCT01868009, titled 'DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)'. This randomized, controlled study enrolled 287 participants in the United States and is now completed.
ELLIPTA DISKUS refers to a combination of two inhaler devices, DISKUS and ELLIPTA, studied together in a clinical trial. The trial compared patient preference between the two devices in chronic obstructive pulmonary disease. ELLIPTA DISKUS is not a single drug but a device combination evaluated by GSK.